Q3 EPS Estimate for Neumora Therapeutics Boosted by Analyst

Key Points

• Analysts at HC Wainwright have raised their Q3 2025 earnings per share estimate for Neumora Therapeutics from ($0.46) to ($0.39).
• Neumora recently reported a quarterly EPS of ($0.33), exceeding analyst expectations by $0.05.
• Institutional investors hold approximately 47.65% of Neumora Therapeutics' stock, with notable increases in stakes from several hedge funds.

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Analysts at HC Wainwright increased their Q3 2025 earnings per share estimates for Neumora Therapeutics in a research report issued on Thursday, August 7th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($0.39) for the quarter, up from their prior forecast of ($0.46). The consensus estimate for Neumora Therapeutics' current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Neumora Therapeutics' Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.54) EPS, Q2 2026 earnings at ($0.44) EPS, Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.38) EPS, FY2026 earnings at ($1.62) EPS, FY2027 earnings at ($1.67) EPS, FY2028 earnings at ($1.27) EPS and FY2029 earnings at ($0.09) EPS.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.33) EPS for the quarter, topping analysts' consensus estimates of ($0.38) by $0.05.

A number of other brokerages have also commented on NMRA. Mizuho lifted their price target on Neumora Therapeutics from $4.00 to $5.00 and gave the stock an "outperform" rating in a report on Wednesday, July 16th. Needham & Company LLC reiterated a "buy" rating and set a $5.00 price target on shares of Neumora Therapeutics in a report on Tuesday, May 13th. One analyst has rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $7.14.

Neumora Therapeutics Stock Performance

Shares of Neumora Therapeutics stock opened at $1.46 on Monday. The business's fifty day simple moving average is $1.24 and its 200 day simple moving average is $1.18. The firm has a market capitalization of $236.15 million, a P/E ratio of -0.93 and a beta of 2.91. Neumora Therapeutics has a 12 month low of $0.61 and a 12 month high of $17.19. The company has a current ratio of 10.54, a quick ratio of 10.54 and a debt-to-equity ratio of 0.11.

Institutional Trading of Neumora Therapeutics

Several hedge funds have recently made changes to their positions in NMRA. Capital International Investors raised its stake in shares of Neumora Therapeutics by 692.1% in the fourth quarter. Capital International Investors now owns 3,700,359 shares of the company's stock valued at $39,224,000 after buying an additional 3,233,179 shares during the period. Lunate Capital Ltd bought a new stake in shares of Neumora Therapeutics in the first quarter valued at $2,124,000. Graham Capital Management L.P. raised its stake in shares of Neumora Therapeutics by 1,643.7% in the first quarter. Graham Capital Management L.P. now owns 1,162,499 shares of the company's stock valued at $1,162,000 after buying an additional 1,095,830 shares during the period. AQR Capital Management LLC bought a new stake in shares of Neumora Therapeutics in the first quarter valued at $463,000. Finally, Stempoint Capital LP purchased a new position in shares of Neumora Therapeutics in the fourth quarter valued at $4,538,000. 47.65% of the stock is currently owned by institutional investors.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.